A phase I study of sequential vaccinations with recombinant Fowlpox-PSA (L155)-TRICOM (rF)alone, or in combination with recombinant vaccinia-PSA (L155)-TRICOM (rV), and the role of GM-CSF, in patients (Pts) with prostate cancerPhilip M. Arlen, Jeffrey Schlom, N R Todd et al.|Journal of Clinical Oncology|2004Cited by 10
Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancerWiem Lassoued, James L. Gulley, Ravi A. Madan et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 8
1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC)Ravi A. Madan, James L. Gulley, Renee N. Donahue et al.|Annals of Oncology|2022Cited by 2